| Resilience and Exercise in Advanced Cancer Treatment (NCT02680990) | Milton S. Hershey Medical Center | 2015-12-01 |
| FDG-PET Directed Treatment in Improving Response in Patients With Locally Advanced Stomach or Gastroesophageal Junction Cancer (NCT02485834) | Alliance for Clinical Trials in Oncology | 2015-11-12 |
| Andecaliximab With mFOLFOX6 as First Line Treatment for Advanced Gastric or Gastroesophageal Junction Adenocarcinoma (NCT02545504) | Gilead Sciences | 2015-10-13 |
| A Study of Ramucirumab (LY3009806) in Combination With Paclitaxel in Participants With Gastric Cancer (NCT02514551) | Eli Lilly and Company | 2015-10-12 |
| A Study of Ramucirumab Plus Pembrolizumab in Participants With Gastric or GEJ Adenocarcinoma, NSCLC, Transitional Cell Carcinoma of the Urothelium, or Biliary Tract Cancer (NCT02443324) | Eli Lilly and Company | 2015-07-29 |
| A Phase 2 Study of Ramucirumab (LY3009806) in Participants With Gastric or Gastroesophageal Junction (GEJ) Cancer (NCT02443883) | Eli Lilly and Company | 2015-07-07 |
| Neoadjuvant SLOT Versus SOX in Patients With Locally Advanced, Resectable Gastric/Esophagogastric Junction (EGJ) Cancer (NCT02512380) | Chinese Academy of Medical Sciences | 2015-07-01 |
| A Study of Pembrolizumab (MK-3475) Versus Paclitaxel for Participants With Advanced Gastric/Gastroesophageal Junction Adenocarcinoma That Progressed After Therapy With Platinum and Fluoropyrimidine (MK-3475-061/KEYNOTE-061) (NCT02370498) | Merck Sharp & Dohme LLC | 2015-05-11 |
| Serum and Peritoneal CEA and CA 19-9 for Gastric Adenocarcinoma (NCT02801955) | Bezmialem Vakif University | 2015-04-01 |
| A Study of Pembrolizumab (MK-3475) in Participants With Recurrent or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma (MK-3475-059/KEYNOTE-059) (NCT02335411) | Merck Sharp & Dohme LLC | 2015-02-03 |
| Genetic Analysis-Guided Irinotecan Hydrochloride Dosing of mFOLFIRINOX in Treating Patients With Locally Advanced Gastroesophageal or Stomach Cancer (NCT02366819) | University of Chicago | 2014-12-11 |
| Effect Study of Clinical Outcomes of Traditional Chinese Medicine to Advanced Gastric Cancer by Propensity Score (NCT02781285) | Shanghai University of Traditional Chinese Medicine | 2014-12-01 |
| Genetic Analysis-Guided Dosing of FOLFIRABRAX in Treating Patients With Advanced Gastrointestinal Cancer (NCT02333188) | University of Chicago | 2014-12-01 |
| Single-arm Study of Selumetinib in Combination With Docetaxel, in Advanced Gastric Adenocarcinoma Patients With Low/High MEK Signature, RAS Mutation or RAS Amplification as a Second-line Chemotherapy (NCT02448290) | Samsung Medical Center | 2014-11-12 |
| Effect of Peritoneal Lavage on Surgery-induced Positive Peritoneal Cytology in Gastric Cancer Patients (NCT02287168) | Bezmialem Vakif University | 2014-10-01 |
| Trial of S-1 Maintenance Therapy in Metastatic Esophagogastric Cancer (NCT02128243) | AIO-Studien-gGmbH | 2014-09-01 |
| A Study of DKN-01 in Combination With Paclitaxel or Pembrolizumab (NCT02013154) | Leap Therapeutics, Inc. | 2014-05-05 |
| A Study of Emibetuzumab in Combination With Ramucirumab (LY3009806) in Participants With Advanced Cancer (NCT02082210) | Eli Lilly and Company | 2014-03-07 |
| MetronomIc CApecitabine and DOcetaxel as Second-line Chemotherapy for Advanced Gastric Cancer (NCT02007148) | International Group of Endovascular Oncology | 2013-11-01 |
| Pilot Study of Perioperative Docetaxel, Oxaliplatin, and 5-Fluorouracil (FLOT) in Gastroesophageal Adenocarcinoma (NCT01932580) | McGill University | 2013-08-01 |
| S-1, Cisplatin-based Chemoradiotherapy, Induction Chemotherapy, Locally Advanced Gastric Adenocarcinoma (NCT02495493) | Yonsei University | 2013-07-01 |
| Oxaliplatin Plus Capecitabine in the Perioperative Treatment of Locally Advanced Gastric Adenocarcinoma (NCT01880632) | Shanghai Zhongshan Hospital | 2013-07-01 |
| Diffusion Weighted Magnetic Resonance Imaging for Preoperative Staging in Gastric Adenocarcinoma Patients (NCT01794026) | Bezmialem Vakif University | 2013-03-01 |
| Study of Sacituzumab Govitecan-hziy (IMMU-132) in Adults With Epithelial Cancer (NCT01631552) | Gilead Sciences | 2012-12-17 |
| Phase II Study of Cabazitaxel in Refractory Metastatic Gastric or Gastroesophageal Adenocarcinoma (NCT01757171) | Weill Medical College of Cornell University | 2012-12-01 |
| Efficacy and Safety Study of ABI-007 Plus Capecitabine as First-line Chemotherapy for Advanced Gastric Cancer Patients (NCT01641783) | Yanqiao Zhang | 2012-07-01 |
| Carnoy's Solution Versus Formalin in Rectal and Gastric Cancer Specimens Following: a Randomized Trial (NCT02629315) | Instituto do Cancer do Estado de São Paulo | 2012-05-10 |
| Dose-dense Biweekly Docetaxel Combined With 5-fluorouracil as First-line Treatment in Advanced Gastric Cancer (NCT01567618) | Sixth Affiliated Hospital, Sun Yat-sen University | 2012-03-01 |
| Using Genetic Polymorphisms to Predict the Efficacy and Toxicity - A Gastric Adenocarcinoma Study (NCT01558011) | National Health Research Institutes, Taiwan | 2012-03-01 |
| SOX Regimen as Neoadjuvant Chemotherapy for AJCC Stage II-III Gastric Cancer (NCT01583361) | Lin Chen | 2012-03-01 |
| Trastuzumab Based Therapy in HER2 Positive AGC (NCT03024450) | Shanghai Zhongshan Hospital | 2012-01-01 |
| Trial of ABI-007 Plus S-1 as Second-line Chemotherapy in Advanced Gastric Cancer Patients (NCT01336062) | Peking University | 2011-04-01 |
| Efficacy and Safety of Panitumumab Combined With Docetaxel and Cisplatin as a First-line Treatment of Advanced Gastric or Gastroesophageal Junction Adenocarcinoma (NCT01379807) | Grupo Gallego de Investigaciones Oncologicas | 2010-12-01 |
| Pralatrexate and Oxaliplatin in Treating Patients With Unresectable or Metastatic Esophageal, Stomach, or Gastroesophageal Junction Cancer (NCT01178944) | Roswell Park Cancer Institute | 2010-09-01 |
| First Line Study of Irinotecan, Capecitabine and Oxaliplatin in Metastatic Gastric or Gastroesophageal Cancer. (NCT01129310) | AHS Cancer Control Alberta | 2010-07-01 |
| Docetaxel and S1 (DS) Versus S1 and Cisplatin (SP) in Curatively Resected Stage IIIB/IV Gastric Cancer (NCT01283217) | Yonsei University | 2010-03-01 |
| Study of MBP-426 in Patients With Second Line Gastric, Gastroesophageal, or Esophageal Adenocarcinoma (NCT00964080) | Mebiopharm Co., Ltd | 2009-05-01 |
| NESC: Neoadjuvant Treatment of Gastric Adenocarcinoma (NCT01565109) | Recherche clinique | 2009-03-01 |
| Irinotecan/Cisplatin, Potentially Curative Surgery With or Without Floxuridine, Followed by Capecitabine for Stomach and Gastro-esophageal Junction (GEJ) Cancers (NCT00848783) | NYU Langone Health | 2008-05-01 |
| Perioperative Panitumumab and Epirubicin, Oxaliplatin and Xeloda (EOX) in Patients With Gastroesophageal Adenocarcinoma (NCT00667420) | Massachusetts General Hospital | 2008-04-01 |
| Efficacy and Safety of Sunitinib in Metastatic Gastric Cancer (NCT00411151) | Johannes Gutenberg University Mainz | 2006-12-01 |
| Safety and Efficacy Study With Catumaxomab in Patients After Curative Resection of a Gastric Adenocarcinoma (NCT00352833) | Neovii Biotech | 2006-07-01 |
| Phase II Trial of Gleevec and Taxotere as a Combined Regimen for Advanced Gastric Adenocarcinoma (NCT00209079) | Emory University | 2004-09-01 |
| Study of 5-Fluorouracil and Leucovorin and Intra-abdominal Floxuridine Chemoradiation in Patients With Fully Resected Locally Advanced Gastric Adenocarcinoma (NCT00183911) | University of Southern California | 2003-11-01 |
| Phase II Study of Single Agent OSI-7904L in Patients With Gastric or Gastroesophageal (GEJ) Cancer (NCT00073502) | OSI Pharmaceuticals | 2003-10-01 |
| Irinotecan and Cisplatin in Treating Patients Who Are Undergoing Surgery For Locally Advanced Cancer of the Stomach or Gastroesophageal Junction (NCT00062374) | National Cancer Institute (NCI) | 2003-06-01 |
| Expanded Access Use of DKN-01 for the Treatment of Advanced Solid Tumors (NCT04681248) | Leap Therapeutics, Inc. | |